Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.
Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company whose news flow centers on the development and regulatory progress of kidney disease therapies. Company press releases highlight advances for its lead investigational product oxylanthanum carbonate (OLC), an oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and for its second program UNI-494, which is intended for conditions related to acute kidney injury.
Investors following UNCY news can expect detailed updates on regulatory interactions with the U.S. Food and Drug Administration, including New Drug Application submissions, Complete Response Letters, Type A meetings, and NDA resubmissions for OLC. The company also reports on pivotal and Phase 2 clinical trial results, analyses of pill burden and phosphate control, and publications of OLC data in peer-reviewed journals such as the Clinical Journal of the American Society of Nephrology.
Unicycive’s news releases frequently cover financial results, cash runway commentary, and capital markets activities, such as at-the-market equity offerings and reverse stock split implementation, as disclosed in associated Form 8-K filings. Additional news items include participation in healthcare and investor conferences, issuance of new patents for UNI-494 and its use in chronic kidney disease, and corporate updates on Nasdaq listing compliance and legal matters, including disclosure of a purported securities class action.
This UNCY news page aggregates these company-issued updates so readers can review clinical data milestones, regulatory developments, intellectual property announcements, and financial disclosures in one place. For those tracking the progress of oxylanthanum carbonate and UNI-494, the news feed provides a chronological view of Unicycive’s communications about its kidney disease pipeline and corporate activities.
Unicycive Therapeutics (Nasdaq: UNCY) announced the acceptance of four abstracts for presentation at the World Congress of Nephrology 2023 in Bangkok from March 30 – April 2. Key presentations will include data on Renazorb's phosphate binding capabilities from a Phase 1 clinical study and preclinical assessments of UNI-494. The company is optimistic about filing a New Drug Application for Renazorb with the FDA mid-2023, which could enhance its market position and partnership opportunities.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has announced the termination of its "at-the-market" equity offering program to mitigate shareholder dilution. The termination process begins immediately and will be finalized on January 8, 2023. The company has not conducted any sales under this offering since December 15, 2022. Unicycive is focused on developing therapies for kidney disease, including its lead drug, Renazorb, for hyperphosphatemia and UNI-494 for acute kidney injury. Additional details are available in the company's recent SEC filing.
Unicycive Therapeutics announced successful results from a pivotal bioequivalence study of Renazorb compared to Fosrenol, meeting the primary endpoint and establishing pharmacodynamic bioequivalence. This finding supports the upcoming New Drug Application submission scheduled for mid-2023. Renazorb, designed to treat hyperphosphatemia in chronic kidney disease patients, aims to reduce the pill burden, potentially improving patient compliance. The global market for hyperphosphatemia treatment exceeds $2.5 billion, with significant unmet needs in patient management.
Unicycive Therapeutics has received acceptance from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its UNI-494 Phase 1 study, targeting patients with acute kidney injury. This first-in-human trial is set to begin in Q1 2023, following successful completion of preclinical safety assessments. UNI-494, which activates mitochondrial KATP channels, is supported by extensive safety data from earlier studies on its active metabolite, nicorandil. The company also plans to file an Investigational New Drug application with the FDA for a Phase 2 trial in 2023.
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) will be featured in an interview on The RedChip Money Report® airing on Bloomberg TV on December 10, 2022, at 7 p.m. ET. CEO Shalabh Gupta will discuss key developments, including data from the upcoming bioequivalence study and the forthcoming Phase 1 trial for the company’s lead program targeting hyperphosphatemia. The interview aims to highlight Unicycive's innovative approaches in treating significant kidney diseases with unmet medical needs.
Unicycive Therapeutics (Nasdaq: UNCY) announced participation in two key conferences to highlight their innovative therapies. The Sequire Technology Conference will feature a company presentation on November 30, 2022, at 11:30 a.m. ET. Additionally, Unicycive will engage in 1x1 meetings at Benchmark’s 11th Annual Discovery Conference on December 1, 2022, at the New York Athletic Club. The company is developing Renazorb for hyperphosphatemia and UNI-494 for mitochondrial dysfunction, targeting unmet medical needs in kidney diseases.
Unicycive Therapeutics (Nasdaq: UNCY) announced third-quarter 2022 financial results and significant business updates. The company has completed enrollment for its pivotal bioequivalence study of RENAZORB, an investigational phosphate binder for hyperphosphatemia in CKD patients, with topline results expected by year-end. They plan to file a New Drug Application (NDA) in 2023. Unicycive has also signed a global partnership for RENAZORB’s commercialization in China, receiving $1 million upfront. Research and development expenses increased to $4.8 million, resulting in a net loss of $5.6 million for the quarter.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has completed subject enrollment in the RENAZORB bioequivalence study, aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The randomized BE study, approved by the FDA, involves 80 subjects and measures urinary phosphate excretion changes. Topline data is expected by year-end 2022, with plans to file a New Drug Application (NDA) in 2023. RENAZORB's unique nanoparticle technology may enhance patient adherence compared to existing treatments. The company anticipates significant market opportunities for this advanced phosphate binder.
Unicycive Therapeutics (Nasdaq: UNCY) is set to showcase its kidney disease therapies at the ASN Kidney Week 2022, scheduled for Nov 3-6, in Orlando, Florida. CEO Shalabh Gupta highlighted the serious issue of hyperphosphatemia in end-stage renal patients and discussed the potential of Renazorb, an advanced phosphate binder, and UNI-494, a candidate for acute kidney injury treatment. Clinical trials for Renazorb have demonstrated its safety and efficacy, significantly reducing phosphate excretion. The company aims to transform treatment for kidney disorders, addressing major compliance challenges.
Unicycive Therapeutics (Nasdaq: UNCY) will present at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. CEO Shalabh Gupta will share insights into the company's late-stage program targeting hyperphosphatemia and an early-stage program addressing mitochondrial dysfunction diseases. Investors can schedule one-on-one meetings through Roth representatives. The firm is advancing its lead drug, Renazorb, a phosphate-binding agent, and UNI-494, a new chemical entity for acute kidney injury treatment. For inquiries, investors can contact ir@unicycive.com.